小细胞肺癌治疗新药: 塔拉妥单抗靶向DLL3/CD3双特异性T细胞衔接器

A new drug for treating small cell lung cancer: tarlatamab, a DLL3/CD3-targeted bispecific T-cell engage

摘要

塔拉妥单抗 (tarlatamab) 是一款创新靶向免疫药物,能够同时结合肿瘤细胞表面表达的δ样配体3 (delta-like ligand 3,DLL3) 和细胞毒性 T 细胞表面表达的 CD3,是靶向 DLL3/CD3 的双特异性 T 细胞衔接器,能够激活 T 细胞释放炎性细胞因子,从而杀伤表达 DLL3 蛋白的肿瘤细胞。2024 年5 月,tarlatamab 获美国 FDA 加速批准,用于治疗在铂类化疗期间或之后进展的广泛期小细胞肺癌 (extensive stage small cell lung cancer,ES-SCLC) 成人患者。本文就 tarlatamab 的基本信息、作用机制、药动学、临床试验研究、安全性进行概述,以期为临床应用提供参考。

Abstract

Tarlatamab is an innovative targeted immunotherapy agent that simultaneously binds to delta-like ligand 3 (DLL3) expressed on tumor cell surfaces and CD3 expressed on cytotoxic T-cell surfaces.As a DLL3/ CD3-targeted bispecific T-cell engager (BiTE), it activates T cells to release inflammatory cytokines, thereby killing tumor cells expressing DLL3 protein.In May 2024, tarlatamab received accelerated approval from the U.S.FDA for the treatment of adult patients with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.This article provides an overview of tarlatamab＇s basic information, mechanism of action, pharmacokinetics, clinical trials, and safety, to provide a reference for clinical application.

关键词

塔拉妥单抗 / 小细胞肺癌 / 双特异性T细胞衔接器 / δ样配体3 / 免疫治疗

Key words

tarlatamab / small cell lung cancer / bispecific T-cell engager / delta-like ligand-3 / immuno-therapy

[1] 中国临床肿瘤学会小细胞肺癌专家委员会,中国医师协会肿瘤多学科诊疗专业委员会.小细胞肺癌免疫治疗专家共识 (2025 版)[J].中华肿瘤杂志,2025,47 (1):65-75.
[2] CHIANG CL,SOO RA,MOK T,et al.A comparison of clinical guidelines,treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America[J]. Front Oncol,2025,15: 1646608.
[3] KIM SY,PARK HS,CHIANG AC.Small cell lung cancer:a review[J].JAMA,2025,333 (21): 1906.
[4] KRPINA K,VRANIĆ S,TOMIĆ K,et al.Small cell lung carci-noma:current diagnosis,biomarkers,and treatment options with future perspectives[J].Biomedicines,2023,11 (7): 1982.
[5] SANDS JM,CHAMPIAT S,HUMMEL HD,et al.Practical management of adverse events in patients receiving tarlatamab,a delta-like ligand 3-targeted bispecific T-cell engager immunother-apy,for previously treated small cell lung cancer[J].Cancer, 2025,131 (3):e35738.
[6] ANTONIU S,PENISOARA T,RASCU S.Tarlatamab for small-cell lung cancer[J].Expert Opin Biol Ther,2025, 25 (12): 1275-1283.
[7] DHILLON S.Tarlatamab:first approval[J].Drugs,2024, 84 (8):995-1003.
[8] AMGEN INC.IMDELLTRA (tarlatamab-dlle) for injection[package insert] [Z].Thousand Oaks:Amgen Inc, 2024.
[9] SU PL,CHAKRAVARTHY K,FURUYA N,et al.DLL3-guided therapies in small-cell lung cancer:from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy[J].Mol Cancer,2024,23 (1): 97.
[10] LIU YF,NASHED J,BARONE AK,et al.FDA approval sum-mary:tarlatamab for the treatment of extensive-stage small cell lung cancer[J].Clin Cancer Res,2026,32 (7):1191-1195.
[11] 国家药品监督管理局药品审评中心.优先审评品种:塔拉妥单抗[EB/OL].(2025-07-08)[2026-03-11].https://www.cde.org.cn/main/xxgk/listpage/2f78f372d351c6851af743 1c7710a731.
[12] CHOU J,EGUSA EA,WANG S,et al.Immunotherapeutic Tar-geting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer[J].Cancer Res,2023,83 (2):301-315.
[13] YAO J,BERGSLAND E,AGGARWAL R,et al.DLL3 as an e-merging target for the treatment of neuroendocrine neoplasms[J]. Oncologist,2022,27 (11):940-951.
[14] KONG S,MINOCHA M,CHEN PW,et al.Population pharma-cokinetics of tarlatamab,a half-life extended DLL3-directed bis-pecific T-cell engager in patients with previously treated small cell lung cancer[J].Clin Pharmacokinet,2025, 64 (5): 729-741.
[15] MINOCHA M,THOMPSON CG,MURPHY A,et al.Pharmaco-kinetics of tarlatamab,a delta-like ligand-3 (DLL3) targeted half-life extended bispecific T-cell engager (BiTE^®) immuno-therapy in adult patients with previously treated small-cell lung cancer:results from DeLLphi-300,a phase I multiple-dose-esca-lation study[J].Clin Pharmacokinet,2024,63 (12): 1757-1768.
[16] CHEN PW,MINOCHA M,KONG S,et al.Tarlatamab expo-sure-efficacy and exposure-safety relationships to inform dose se-lection in patients with small cell lung cancer[J].Clin Cancer Res,2025,31 (22):4688-4697.
[17] AHN MJ,CHO BC,FELIP E,et al.Tarlatamab for patients with previously treated small-cell lung cancer[J].N Engl J Med,2023,389 (22):2063-2075.
[18] AHN MJ,CHO BC,OHASHI K,et al.Asian subgroup analysis of patients in the phase 2 DeLLphi-301 study of tarlatamab for previously treated small cell lung cancer[J].Oncol Ther,2025, 13 (4):1041-1054.
[19] 中国医师协会肿瘤医师分会,中国临床肿瘤学会,中华医学会肿瘤学分会.IV期原发性肺癌中国治疗指南 (2024版)[J].中华肿瘤杂志,2024,46 (1):1-40.
[20] 中国抗癌协会肺癌专业委员会.中国肺癌免疫治疗规范化应用指南 (2024版)[J].中国肺癌杂志,2024,27 (1):1-56.
[21] MOUNTZIOS G,SUN LH,CHO BC,et al.Tarlatamab in small-cell lung cancer after platinum-based chemotherapy[J].N Engl J Med,2025,393 (4):349-361.
[22] WANG J,SAJEEV G,CHAI XL,et al.Efficacy outcomes be-tween tarlatamab and real-world physicians＇choice of therapies for previously treated extensive stage small cell lung cancer[J].On-cologist,2025,30 (9):oyaf256.
[23] TAKUNDWA R,SURI G,DIRNBERGER F,et al.Matching-adjusted indirect treatment comparison of tarlatamab versus com-parator therapies in England in patients with extensive-stage small cell lung cancer who have received two or more prior lines of ther-apy[J].Adv Ther,2025,42 (12):6078-6090.
[24] CHAMPIAT S,BOYER MJ,GOVINDAN R,et al.Tarlatamab in small cell lung cancer (SCLC):Safety and efficacy analyzed by baseline brain metastasis[J].J Clin Oncol,2023,41 (16_suppl):S8582.
[25] ZHANG BN,SHAH K,PARMA M,et al.Trls-17 rapid in-tracranial response with tarlatamab in patients with untreated brain metastases from small cell lung cancer[J].Neuro Oncol Adv,2025,7 (Supplement_2):ii37.
[26] LAU S,AHN MJ,MOSKOVITZ M,et al.OA10. 04 tarlatamab with a PD-L1 inhibitor as first-line maintenance after chemo-im-munotherapy for ES-SCLC:DeLLphi-303 phase 1b study[J].J Thorac Oncol,2024,19 (10):S31-S32.
[27] PAULSON KG,LAU SCM,AHN MJ,et al.Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303):a multi-centre,non-randomised,phase 1b study[J].Lancet Oncol, 2025,26 (10):1300-1311.
[28] ClinicalTrials.gov.NCT06788938[EB/OL].[2026-03-20]. https://clinicaltrials.gov/study/NCT06788938.
[29] ClinicalTrials.gov.NCT06816394[EB/OL].(2025-02-10). https://clinicaltrials.gov/study/NCT06816394.
[30] ClinicalTrials.gov.NCT06745323[EB/OL].[2026-03-03]. https://clinicaltrials.gov/study/NCT06745323.
[31] ClinicalTrials.gov.NCT06893783[EB/OL].[2026-04-13]. https://clinicaltrials.gov/study/NCT06893783.
[32] ClinicalTrials.gov.NCT06830694[EB/OL].[2026-02-23]. https://clinicaltrials.gov/study/NCT06830694.
[33] ClinicalTrials.gov.NCT06814496[EB/OL].(2025-10-09). https://clinicaltrials.gov/study/NCT06814496.
[34] ClinicalTrials.gov.NCT05361395[EB/OL].[2026-03-03]. https://clinicaltrials.gov/study/NCT05361395.
[35] ClinicalTrials.gov.NCT06776250[EB/OL].(2025-09-19). https://clinicaltrials.gov/study/NCT06776250.
[36] ClinicalTrials.gov.NCT06898957[EB/OL].[2026-02-05]. https://clinicaltrials.gov/study/NCT06898957.
[37] ClinicalTrials.gov.NCT05060016[EB/OL].(2025-12-12). https://clinicaltrials.gov/study/NCT05060016.
[38] PAZ-ARES L,AHN MJ,FELIP E,et al. 508 MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC):Primary analysis of the phase II DeLLphi-301 study[J].Ann Oncol,2023,34:S1664-S1665.
[39] CHIANG AC,OLMEDO GARCIA ME,CARLISLE JW,et al.Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1:DeLLphi-300 phase 1 substudy[J]. ESMO Open,2025,10 (4): 104538.
[40] JIN XN,ZHAO WX,LI Y,et al.Post-marketing safety surveil-lance of tarlatamab:a real-world pharmacovigilance study based on the FAERS database[J].Naunyn Schmiedeberg＇s Arch Phar-macol,2026 (1):1-14.
[41] WANG JS,WANG X,LI YX,et al.Safety evaluation of tarlata-mab:a pharmacovigilance study based on the FAERS database[J].Lung Cancer,2026,214: 108801.
[42] JOSHI U,ONG F,MELZER D,et al.Optimizing tarlatamab de-livery in small cell and neuroendocrine lung cancer:real-world insights into step-up dosing and prophylactic tocilizumab use[J]. Clin Lung Cancer,2026,27 (2):48-58.
[43] ZHANG BN,ALDER L,ROSNER S,et al.A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS[J].Lung Cancer,2026,211: 108870.
[44] AHN HM,PARK SY,CHOI Y,et al.Molecular subtype chan-ges after acquiring resistance to tarlatamab in small cell lung cancer[J].Drug Resist Updat,2025,79: 101198.

基金资助

山东省中医药科技资助项目(M20241206);山东省医学会临床科研基金资助项目-齐鲁专项(YXH-2022ZX02069);山东第二医科大学附属医院科研发展基金资助项目(2024FYM146)